BERENBERG Maintains Eurofins Scientific SE (ERFSF) Hold Recommendation

Berenberg on Dec. 10 maintained a Hold on Eurofins Scientific (OTCPK: ERFSF); the consensus one‑year price target is $75.52 (range $55.70–$109.77), implying ~27.4% upside from the Dec. 6 close of $59.27. Analysts project annual revenue of 7,413MM (up 3.76%) and non‑GAAP EPS of 4.07. Institutional interest is broad—251 funds hold positions (up 1.21% quarter‑over‑quarter) and average portfolio weight rose to 0.31% (+4.29%)—but total institutional shares fell 1.35% to 26,110K as several large active managers (notably Oakmark and Europacific) trimmed stakes while others (Sequoia, FPA) were steady and Vanguard made a small allocation change. The juxtaposition of a material consensus upside and recent trimming by major active holders suggests investor sentiment is mixed and the stock may remain sensitive to near‑term results and fund flow dynamics.

Analysis

Berenberg on December 10 maintained a Hold on Eurofins Scientific (OTCPK: ERFSF); the consensus one‑year price target as of December 6 is $75.52 (range $55.70–$109.77), implying approximately 27.41% upside from the latest reported close of $59.27. Analysts project annual revenue of $7,413MM (up 3.76%) and non‑GAAP EPS of 4.07, indicating modest top‑line growth baked into current forecasts.

Institutional positioning is mixed: 251 funds report positions (an increase of 3 owners or 1.21% quarter‑over‑quarter) and average portfolio weight rose to 0.31% (+4.29%), yet total institutional shares declined 1.35% to 26,110K. Notable active managers trimmed exposure—Oakmark to 3,782K shares (reported 30.06% reduction) and EUROPACIFIC to 1,815K with a stated allocation decrease—while Sequoia and FPA Crescent remained steady and Vanguard made a small allocation change, signaling divergent conviction among large holders.

The combination of a material consensus upside, a Hold analyst view, and active‑manager trimming suggests the stock is sensitive to near‑term earnings and fund flows; sentiment metrics are mildly positive (0.25) but market‑impact is low (0.18), so absent a clear catalyst price moves may be muted. Investors should watch upcoming quarterly results and subsequent 13F disclosures as the principal catalysts that could validate the upside or trigger additional outflows and downside pressure.

Key Decisions for Investors

• Monitor upcoming earnings and next 13F filings closely and avoid adding meaningful size ahead of those catalysts
• If considering entry, use a staged buy‑on‑weakness approach targeting the consensus $75.52 anchor while limiting position size given recent active‑manager trimming
• For existing holders, consider trimming or hedging exposure ahead of near‑term results and track institutional share trends for signs of sustained flow outflows